Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198536 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT00198536: Completed Phase 2 study, sponsored by Bausch & Lomb Incorporated.
NCT00198536 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 159 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00198536, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ecabet ophthalmic solution is an effective treatment for dry eye syndrome
Primary Outcome
Group mean change in ocular discomfort score from pre-Cataract extraction (CAE) to post-CAE
Interventions
- DRUG Vehicle
- DRUG Ecabet 2.83%
- DRUG Ecabet 3.70%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2005-04 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00198536 record still lists
NCT00198536 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT00198536 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00198536 about?
NCT00198536 is a clinical study titled "Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome". The purpose of this study is to determine whether ecabet ophthalmic solution is an effective treatment for dry eye syndrome
What is the current status of trial NCT00198536?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2005-04. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00198536?
The interventions under investigation include: Vehicle (DRUG), Ecabet 2.83% (DRUG), Ecabet 3.70% (DRUG).
Who is sponsoring clinical trial NCT00198536?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00198536's enrollment target sits among peer trials
159 442nd of 2000 higher than 1,558 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia